Company Reports Positive Preclinical Results for MitoXcel™ in Aged Rats
What happened
The Company announced interim results from a study of its lead MitoXcel™ geropeptide, PTC-2105, in aged rats. The preclinical testing was conducted at the BIO-VITAL Program Preclinical Testing Core facility of Albert Einstein College of Medicine under a fee-for-service agreement. Results showed that PTC-2105 preserved motor performance and increased fat-mass loss in the oldest rats compared to the vehicle group.
From manilatimes.net
Why it matters
The findings are consistent with prior observations in aged mice and provide second-species information to support the Company’s Investigational New Drug program. These results support the Company's target for first-in-human trials in 2027.
From manilatimes.net
Who's involved
- CompanyBiotechnology company developing mitochondria-targeted geropeptides
- Albert Einstein College of MedicineFacility where the Company conducted preclinical testing
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Albert Einstein College of MedicineSpeculative
Albert Einstein College of Medicine might generate direct revenue from the fee-for-service agreement.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Company
Direct Mail Division of FSSI
-
Albert Einstein College of Medicine
private medical school in New York City, NY
Nothing else this week.